Bioretec

0.73 EUR

+8.63 %

1,698 following

BRETEC

First North Finland

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

Compare

+8.63 %

-15.31 %

-44.70 %

-58.99 %

-68.25 %

-67.71 %

-51.15 %

-74.08 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Market cap

22.48M EUR

Turnover

212.96K EUR

P/E (adj.) (25e)

EV/EBIT (adj.) (25e)

P/B (25e)

EV/S (25e)

Dividend yield-% (25e)

Coverage

Recommendation

Accumulate

Target price

Updated

14.11.2025

Disclaimer

Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 14.11.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk

Business risk

Valuation risk

Low

High

All

Research

Webcasts

Press releases

ShowingAll content types

Regulatory press release41 minutes ago

Inside information: Bioretec updates its strategy for 2026-2028 and provides new financial targets

Bioretec

Regulatory press releaseyesterday

Inside information: Bioretec has been granted FDA Breakthrough Device Designation status for its RemeOs™ DrillPin

Bioretec

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

14:40

Video12/9/2025, 9:09 PM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Create account

Press release12/4/2025, 10:00 AM

Change negotiations completed at Bioretec

Bioretec

Research11/14/2025, 11:18 AM by

Antti Siltanen

Bioretec: Building a new beginning

Bioretec’s Q3 business review highlighted the company’s situation and the commercial challenges of the RemeOs product family.

Bioretec

Regulatory press release11/13/2025, 6:30 AM

Bioretec Ltd's business review January-September 2025: Strengthening commercial foundations and strategy design

Bioretec

Regulatory press release11/12/2025, 10:30 AM

Inside information: Bioretec initiates change negotiations to enance operational efficiency and competitiveness

Bioretec

Regulatory press release10/31/2025, 6:30 AM

Correction: Bioretec Ltd's Half-year report 2025

Bioretec

Regulatory press release10/27/2025, 7:14 PM

Inside information: Bioretec adjusts and restates previously reported net sales FOR H1/2025 and does not expect accelerated sales in 2025

Bioretec

Regulatory press release10/27/2025, 8:00 AM

Inside information: Bioretec is revising its financial targets, deems that the current financial targets will not be met and withdraws its financial targets

Bioretec

Press release10/1/2025, 12:00 PM

Bioretec's RemeOs™ Trauma Screw Approved for Transitional Pass-Through Payment in the U.S.

Bioretec

Press release10/1/2025, 12:00 PM

Bioretec's RemeOs™ Screw LAG Solid Receives CMS Transitional Pass-Through Payment in the US

Bioretec

Regulation of medical devices and diagnostics in Europe

Analyst Comment9/19/2025, 5:18 AM by

Antti Siltanen

Regulation of medical devices and diagnostics in Europe

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

Bioretec Aiforia Technologies Nexstim Biohit Optomed Revenio Group Modulight Detection Technology Nightingale Health Bittium

Regulatory press release9/16/2025, 4:30 PM

Composition of Bioretec's Shareholders' Nomination Board

Bioretec

Regulatory press release9/15/2025, 2:30 PM

Inside information: Anne-Mari Matikainen appointed as Interim Chief Financial Officer of Bioretec; CFO Johanna Salko to depart before year-end

Bioretec

Regulatory press release9/15/2025, 12:15 PM

Antti Siltanen

Classification of medical devices and regulatory processes in the United States

We continue our series of articles focusing on Life Science investing, the first four parts of which focused on drug development. Subsequent articles will cover medical devices.

Bioretec Nexstim Optomed Revenio Group Modulight Bittium Detection Technology

Press release9/2/2025, 12:15 PM

Bioretec Appoints Jordy Winters as Vice President of OUS Sales to Accelerate International Growth

Bioretec

Forum discussions

Something positive for a change. Bioretec has been granted U.S. Food and Drug Administration (FDA) Breakthrough Device Designation status. Time will tell if that turns into money at some point. Bioretec Tiedotteet | Bioretec Bioretec on suomalainen, globaalisti toimiva lääkinnällisi...

yesterday

by makuasia

Investors have certainly had to wait, and are still waiting quite patiently, for this to break through. In my opinion, the product itself, its purpose, and the benefits it brings are quite a no-brainer deal from the consumer’s perspective. However, commercialization and sales haven...

12/8/2025, 11:19 AM

Here are Antti’s comments regarding this latest release. Bioretec announced on Sunday that the U.S. Food and Drug Administration (FDA) has granted its RemeOs-DrillPin Breakthrough Device Designation status. The news is a positive indication of the company’s technology potential and...

yesterday

by Sijoittaja-alokas

Here is a new company report on Bioretec from Antti. Bioretec’s Q3 business review shed light on the company’s situation and the commercial challenges of the RemeOs product family. Growth for the new product family is expected to be delayed until 2026. The company is seeking new ...

11/14/2025, 5:52 AM

by Sijoittaja-alokas

Here are Mr. Siltanen’s comments on how Bioretec’s change negotiations have been concluded. Bioretec announced on Thursday that it had concluded the change negotiations initiated in November. As a result of the negotiations, the company will lay off two employees and furlough five...

12/5/2025, 6:16 AM

by Sijoittaja-alokas

Thanks for this. It makes you think…we are comfortably in the red, but nothing is (yet) lost.

12/8/2025, 1:10 PM

by Cezeta

I have been considering adding to my investment while the valuation is at rock bottom. But… this is quite a rollercoaster when looking at the numbers. What has gone wrong? Is the product not being marketed understandably? Or is it being marketed to the wrong audiences? Are the efforts...

12/8/2025, 9:50 AM

by Cezeta

Bioretec

0.73 EUR

+8.63 %

Coverage

Latest research

Revenue and EBIT-%

EPS and dividend

Risk

Inside information: Bioretec updates its strategy for 2026-2028 and provides new financial targets

Inside information: Bioretec has been granted FDA Breakthrough Device Designation status for its RemeOs™ DrillPin

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Join Inderes community

FREE account

PREMIUM account

Change negotiations completed at Bioretec

Bioretec: Building a new beginning

Bioretec Ltd's business review January-September 2025: Strengthening commercial foundations and strategy design

Inside information: Bioretec initiates change negotiations to enance operational efficiency and competitiveness

Correction: Bioretec Ltd's Half-year report 2025

Inside information: Bioretec adjusts and restates previously reported net sales FOR H1/2025 and does not expect accelerated sales in 2025

Inside information: Bioretec is revising its financial targets, deems that the current financial targets will not be met and withdraws its financial targets

Bioretec's RemeOs™ Trauma Screw Approved for Transitional Pass-Through Payment in the U.S.

Bioretec's RemeOs™ Screw LAG Solid Receives CMS Transitional Pass-Through Payment in the US

Regulation of medical devices and diagnostics in Europe

Composition of Bioretec's Shareholders' Nomination Board

Inside information: Anne-Mari Matikainen appointed as Interim Chief Financial Officer of Bioretec; CFO Johanna Salko to depart before year-end

New shares of Bioretec Ltd subscribed with option rights have been registered with the trade register

Inside information: Bioretec updates the commercialization status of RemeOs™ DrillPin

Bioretec Appoints Dr. Christopher W. DiGiovanni to Scientific Advisory Board

Classification of medical devices and regulatory processes in the United States

Bioretec Appoints Jordy Winters as Vice President of OUS Sales to Accelerate International Growth

Forum discussions